Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18989049 | 1.00 | HSD11B1 (0.31) | HSD11B1 | |
| SCHEMBL18989047 | 1.00 | HSD11B1 (0.31) | HSD11B1 | |
| Hydrochloric Acid SCHEMBL19994949 | 0.97 | HSD11B1 (0.30) | HSD11B1 | |
| Hydrochloric Acid SCHEMBL21407146 | 0.97 | HSD11B1 (0.30) | HSD11B1 | |
| SCHEMBL25641580 | 0.80 | HSD11B1 (0.31) | HSD11B1 | |
| Hydrochloric Acid SCHEMBL21403890 | 0.79 | HSD11B1 (0.30) | HSD11B1 | |
| Hydrochloric Acid SCHEMBL30592814 | 0.79 | HSD11B1 (0.30) | HSD11B1 | |
| Hydrochloric Acid SCHEMBL20241320 | 0.79 | HSD11B1 (0.30) | HSD11B1 | |
| SCHEMBL15540854 | 0.77 | — | — | |
| SCHEMBL26115380 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074901-A1 | NOVEL HETEROARYL COMPOUNDS | ANGELINI PHARMA S.P.A. (IT) | 2025-03-06 | — | — | US | disclosed |
| CN-109715608-B | Indazole compounds for use in tendon and/or ligament injuries | 诺华股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-3515913-B1 | AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | NOVARTIS AG (CH) | 2022-05-11 | — | — | EP | disclosed |
| US-11203595-B2 | Aza-indazole compounds for use in tendon and/or ligament injuries | NOVARTIS AG (CH) | 2021-12-21 | — | — | US | disclosed |
| US-20210188842-A1 | AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | NOVARTIS AG (CH) | 2021-06-24 | — | — | US | disclosed |
| EP-3515894-B1 | INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | NOVARTIS AG (CH) | 2021-04-07 | — | — | EP | disclosed |
| US-10766894-B2 | Aza-indazole compounds for use in tendon and/or ligament injuries | NOVARTIS AG (CH) | 2020-09-08 | — | — | US | disclosed |
| US-20190300522-A1 | AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. | 2019-10-03 | — | — | US | disclosed |
| EP-3515894-A1 | INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | Novartis AG (CH) | 2019-07-31 | — | — | EP | disclosed |
| EP-3515913-A1 | AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | Novartis AG (CH) | 2019-07-31 | — | — | EP | disclosed |
| US-10112907-B2 | Substituted indazoles for treating tendon and/or ligament injuries | NOVARTIS AG (CH) | 2018-10-30 | — | — | US | disclosed |
| US-20180086716-A1 | Indazole Compounds for Use in Tendon and/or Ligament Injuries | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2018-03-29 | — | — | US | disclosed |
| WO-2018055550-A1 | INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | NOVARTIS AG (CH) | 2018-03-29 | — | — | WO | disclosed |
| WO-2018055551-A1 | AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | NOVARTIS AG (CH) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074901-A1 | NOVEL HETEROARYL COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP3A43, F12 | HSD11B1 172/4885 |
| US-10766894-B2 | Aza-indazole compounds for use in tendon and/or ligament injuries | MMP1, TIMP3, ALPI | HSD11B1 220/4885 |
| US-10112907-B2 | Substituted indazoles for treating tendon and/or ligament injuries | SLC10A2, MMP1, TNNI3 | HSD11B1 114/4885 |
| US-20190300522-A1 | AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | MMP1, TIMP3, ALPI | HSD11B1 220/4885 |
| US-20210188842-A1 | AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | MMP1, ALPI, TIMP3 | HSD11B1 221/4885 |
| US-20180086716-A1 | Indazole Compounds for Use in Tendon and/or Ligament Injuries | MMP1, SLC10A2, TNNI3 | HSD11B1 151/4885 |
| US-11203595-B2 | Aza-indazole compounds for use in tendon and/or ligament injuries | MMP1, ALPI, TIMP3 | HSD11B1 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.